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Antibiotic Review: Focus on Older Adults 
Abstract 
Learning Objectives: 
• Discuss spectrum of activity of antimicrobials commonly prescribed to geriatric patients. 
• Review antimicrobial adverse reactions and drug interactions that occur in the geriatric 
population. 
• Determine appropriate antimicrobial dosing recommendations for geriatric patients. 
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 Discuss spectrum of activity of antimicrobials commonly prescribed to geriatric 
patients. 
 
 Review antimicrobial adverse reactions and drug interactions that occur in the 
geriatric population. 
 
 Determine appropriate antimicrobial dosing recommendations for geriatric 
patients. 
 
Narrow 
Spectrum 
Renal 
Function 
Adverse 
Drug 
Reactions 
Drug-Drug 
Drug-Disease 
Interactions 
Allergies 
Right Antibiotic 
C. Difficile 
Risk 
Cost 
Lower Risk of C.difficile Higher Risk of C.difficile 
Nitrofurantoin 
Sulfamethoxazole-trimethoprim 
Fosfomycin 
Aminoglycosides 
Tetracyclines 
Penicillin 
Macrolides 
Fluoroquinolones* 
Clindamycin 
Cephalosporins 
Carbapenems 
 
Owens RC Clin Infect Dis 46:S19-S31. Stevens V. Clin Infect Dis 53:42-48 
*Risk of Clostridium difficile (NAP-1 strain) 
Strep Staph Enterococcus E. Coli 
Klebsiella 
Proteus 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
Penicillin + - + - - - - - 
Amoxicillin 
Ampicillin + - + ± ± 
 
- - - 
Dicloxacillin + MSSA - - - - - - 
Amoxicillin-
clavulanic acid + 
MSSA + + + - - + 
%F Food effect on 
Absorption 
Half-life 
(hours) 
Dosing % Unchanged 
in Urine 
Penicillin VK 60-70 Yes 0.5 4x daily 26-65% 
Ampicillin 30-55 Yes 0.7 – 1.4 4x daily 90% 
Amoxicillin 75-90 No 0.7 – 1.4 3x daily 60% 
Dicloxacillin 35-75 Yes 0.3 – 0.9 4x daily 56-70% 
Amoxicillin-
clavulanic 
acid 
75-90 No 
(amoxicillin) 
Yes  
(clavulanic acid) 
0.7 – 1.4 2-3x daily 60%  
25-40% 
Terico A, Journal of Pharm Practice 2014;27:530-544. 
Penicillin is the leading cause of drug-induced 
anaphylaxis – 0.01 – 0.04% of patients. 
5-10% of the population report an allergy to 
penicillin. 
80 – 90% of patients who report a penicillin 
allergy are not truly allergic! 
Elderly: Immune response wanes over time 
1. What was the reaction? 
2. How long after taking the med, did the reaction 
appear? 
3. How long ago did the reaction happen? 
4. Have you received a cephalosporin? 
5. Have you taken the drug again? 
6. What other meds were taken when rxn occurred? 
 
Blumenthal KG Ann Allergy Asthma Immunol 2015;115:294-300 
 Amoxicillin and ampicillin are associated with the 
development of a delayed maculopapular rash in 
approximately 5% to 10% of patients.  
 
Amoxicillin-clavulanic acid is the most commonly cause of 
drug induced liver injury 
 
Unlike other antibiotics, Dicloxacillin DECREASES INR’s 
Terico A, Journal of Pharm Practice 2014;27:530-544/. LiverTox. Available online: http://livertox.nlm.nih.gov 
Strep Staph Enterococcus E. Coli 
Klebsiella 
Proteus 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
1st generation 
Cephalexin + 
MSSA - + ± - - - 
2nd generation 
Cefuroxime 
axetil 
+ MSSA - + + 
 
- - - 
3rd generation 
Cefpodoxime 
proxetil 
+ MSSA - + + - - - 
Predicts susceptibility to: cephalexin, cefuroxime axetil, cefprozil, cefaclor, cefdinir, cefpodoxime proxetil 
Schuetz AN Diagnostic Microbiol Infect Dis 2013;77:380-384 
 Patients with a true penicillin allergy have a 0.1% to 6% 
cross reactivity with cephalosporins. 
 
 Risk of C.difficile increases with cephalosporin 
generation 
 
 Individualize dosing: cephalexin example for SSTI 
 < 60 kg – 500mg 4 times daily 
 60-80 kg – 1g 3 times daily 
 >80 kg – 1g 4 times daily 
 
 Cefpodoxime proxetil/cefuroxime axetil interact with 
antacids/H2 antagonists 
 Decreases bioavailability.  Administer at least 2 hours 
after administration of H2 antagonist/antacids. 
 
 
Side Chain Similarities 
Ampicillin 
Amoxicillin 
Cefaclor 
Cefadroxil 
Cefprozil 
Cephalexin 
Terico A, Journal of Pharm Practice 2014;27:530-544/Pallin CID 2013;56:1754-62 Owens R CID 2008;46:S19-31  
CAN NOT BE USED TO TREAT SYSTEMIC INFECTIONS, 
PYELONEPHRITIS, OR PROSTATITIS 
Strep Staph Enterococcus E. Coli 
Klebsiella 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
Nitrofurantoin + MSSA 
CoNS 
+ 
(VRE) 
+ 
(ESBL) 
Not 
Proteus 
- - - - 
 Nitrofurantoin microcrystal (Furadantin): 100mg po 4x/day 
 Nitrofurantoin macrocrystal (Macrodantin) 
 Larger, crystal form of nitrofurantoin 
 Absorption is slower  
 Less GI problems compared to microcrystal formulation 
 Take with food to improve bioavailability 
 Dose: 50-100mg 4 times/day 
 Nitrofurantoin monohydrate macrocrystals (Macrobid) 
 Contains 2 forms of nitrofurantoin 
 25% - macrocrystalline 
 75% - monohydrate contained in powder blend, that 
when exposed to gastric and intestinal fluids forms a gel 
matrix that releases over time 
 Take with food to improve bioavailability 
 Dose: 100mg po bid 
CID 2011;52:1212-1217 
eGFR 
(ml/min/1.73m2) 
# of Patients Ineffective  
Adjusted HR (95% CI) 
Serious ADR 
Adjusted HR (95% 
CI) 
> 80 1859 1.0   (reference) 1.0 
50-80 1842 0.92 (0.78-1.08) 
30-49 166 1.06 (0.74 – 1.51) 4.13 (1.31-13.09) 
10-29 20 1.57 (0.7 – 3.52) 
<10 1 N/A 
Geerts AF Eur J Clin Pharm 2013;69:1701, American Geriatrics Society J Am Geriatr Soc 2015;63:2227-2246 
 
Danish Retrospective Cohort Study in Females with Uncomplicated UTIs 
Efficacy: Creatinine clearance threshold to achieve an 80% cure rate 
Gram Negative = 58 ml/min 
Gram Positive = 98 ml/min 
No cultures obtained = 32 ml/min  
Ingalsbe ML Ther Adv Urol 2015;7(4):186-193 
• Peripheral Neuropathy 
• More common in patients with impaired renal function 
 
• Hepatitis 
• Acute or Chronic 
 
• Pulmonary Toxicity 
• Acute onset – within 9 days of exposure 
• Symptoms: cough, dyspnea, chest pain, fever, rash, arthralgias 
• Hypersensitivity reaction (eosinophilia) 
• Reversible 
 
• Chronic onset – up to 6 months to years after exposure 
• Symptoms: insidious onset of cough and progressive dyspnea 
• Direct toxicity: Can be permanent 
 
 
• Avoid nitrofurantoin UTI prophylaxis longer than 6 months and avoid use in 
patients with chronic pulmonary conditions. 
 
Strep Staph Enterococcus E. Coli 
Klebsiella 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
TMP-SMX +* MSSA 
CoNS 
MRSA 
- 
 
+ ± - - - 
*TMP-SMX has activity against S.pneumoniae, but does not 
have good activity against Group A streptococcus. 
  GI: nausea, diarrhea, vomiting 
 Hypersensitivity reactions – rashes and fever (more common in HIV patients) Steven 
Johnson syndrome 
 Hematologic - thrombocytopenia, leukopenia, megaloblastic anemia  - G6PD deficiency 
 Renal 
 Crystalluria 
 Acute Interstitial Nephritis 
 Acute Tubular Necrosis 
 False elevation of serum creatinine in patients with decreased renal function 
due to blocking of secretion 
 Hyperkalemia 
 Acute psychosis 
 Dose related/concomitant use of corticosteroids 
 
Blocks 
secretion 
Acute Interstitial 
Nephritis 
 
Acute Tubular 
Necrosis 
Crystallization 
in the urine 
 Structurally related to 
potassium sparing 
diuretics 
Gentry CA Ann Pharmacother 2013;47:1618-1626 
Variables independently associated with acute renal injury: 
 
Baseline elevated serum creatinine     OR 2110 (95% CI = 724 – 7980)  p< 0.0001 
High dose TMP-SMX (> 5mg/kg/day trimethoprim)  OR 3.70  (95% CI = 1.70-8.12)   p< 0.0012 
Concomitant receipt of an ACEI                                  OR 2.36 (95% CI = 1.01 – 5.24   p<0.048 
Concomitant receipt of a K+ supplement   OR 4.10 (95% CI = 1.45 – 10.1)  p<0.010 
 
Fralick M. BMJ 2014;349:g6196, Antonious T Arch Intern Med 2010;170:1045-1049. , Antonious T CMAJ 2015;187:E138-E143 
> 66 years old on a ACEI or ARB 
Sudden death:   spironolactone  OR 2.46  95% CI (1.55 – 3.90) 
Hospital admission:  spironolactone  OR 12.4  95% CI (7.1 – 21.6) 
 
 
 
Antibiotics: Inhibit 
Erythromycin-3A4 
Clarithromycin- 3A4 
Ciprofloxacin – 1A2 
 
Antibiotics Induce: 
Rifampin 
Antibiotics: 
Inhibit 
TMP-SMX 
Metronidazole 
 
Antibiotics 
induce: 
Rifampin 
Medication Mean change in INR % of pts INR > therapeutic 
Terazosin -0.145 5 
Azithromycin 0.51 31 
Levofloxacin 0.85 33 
TMP-SMX 1.76 69 
J Gen Intern Med. 2005 July; 20(7): 653–656. Hale S Drug Metab Drug Interact 2014; 29(1): 53-60 
 
Avoid use if possible 
 
If must be used together: 
• Monitor INR within 3-4 days 
• Decrease warfarin dose by 25 – 40% 
 Can be used in patients with sulfa allergy 
 
 Less effect on warfarin metabolism 
 Sulfamethoxazole inhibits CYP2C9 
 
 Treatment Dose: Trimethoprim 200mg po BID x 5 – 7 days 
 
 Prophylaxis Dose: Trimethoprim 100mg po daily 
 
 ? Testing 
 
 
 
Hale SF Drug Metab Drug Interact 2014;29(1):53-60 
Strep Staph Enterococcus E. Coli 
Klebsiella 
Proteus 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
Fosfomycin + MSSA 
MRSA 
CoNS 
+ 
(VRE) 
+ 
(ESBL) 
(CRE) 
- ± 
 
- - 
Can NOT be used for the treatment of pyelonephritis 
Monurol Package Insert, CID 2011;52:1212-1217  Reffert JL. Pharmacotherapy 2014;34:845-857 
Property Data 
Bioavailability 37% fasting, 30% fed 
Volume of Distribution 136.1 ± 44.1 L 
Elimination Excreted unchanged in urine (38%) and 
feces (18%) 
Plasma Half-life 5.7 ± 2.8 hrs 
Maximum urinary concentration following 
one 3g dose 
< 4415 mg/L within 4 hrs 
Renal insufficiency Half-life increases to 11-50 hrs, % excreted 
in urine decreases 
CLSI breakpoint ≤ 64 mg/L  (≤32 mg/L) EUCAST 
Adverse effect Diarrhea 
 Uncomplicated UTI: 3g powder packet, dissolve in 3-4 ounces of water x 1 
dose. 
 
 Complicated UTI/Resistant organisms: 3g PO q 48h-72 hrs x 6-21 days 
 3 doses for complicated UTIs 
 
 UTI prophylaxis: 3g PO q weekly 
 
 Acute prostatitis: 3g PO daily  (n=2) 
Reffer JL. Pharmacotherapy 2014;34:845-857, Grayson MI Clin Infect Dis 2015;61:1141-1143 
Organism Number of 
Patients 
Cure Rate 
ESBL 8 100% 
Enterococcus 14 86% 
Pseudomonas 9 78% 
 
 
 
 
Doses prescribed:  1 dose approx. 50%, q 48h x 3 doses (14%), q 72h x 3 doses (35%) 
 
 
Jacobson S. Antimicrob Agents Chemother 2016:60:1952 
Patients with complicated UTI’s, median age 75 years 
Cure Rate – 83%  Recurrence Rate = 3%  
Strep Staph Enterococcus E. Coli 
Klebsiella 
Proteus 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
Ciprofloxacin - ± ± 
 
+ + + + - 
Levofloxacin + ± 
 
± 
 
+ + + + - 
Moxifloxacin + ± 
 
± 
 
+ + - + + 
 GI: nausea, abdominal discomfort, vomiting, diarrhea 
 Allergic: rash, pruritus 
 Endocrine: hypo/hyperglycemia 
 Hepatic – liver failure 
 Renal – nephritis, nephropathy, crystalluria 
 Cardiac: prolongation of the QTC interval 
 CNS: confusion, headache, dizziness, agitation, anxiety, restlessness, 
hallucinations, depression, sleep disturbances, seizures 
 Musculoskeletal: 
 Tendinitis, tendon rupture 
 Peripheral neuropathy 
 Avoid in patients with myasthesia gravis 
Wallace J. Med Clin N Am 2015;99:295-310 
 
 FDA-Approved Medication Guide  
MEDICATION GUIDE 
 Drug Interactions with medications that increase QTc or increase   
concentrations 
 Cardiac Abnormalities 
AV Block/Bradycardia/Sinoatrial block  
Prolonged baseline QT interval > 450 msec 
 Structural Cardiac Disease 
Valvular disease, cardiomyopathy, heart failure, MI 
 Electrolyte imbalances 
Hypokalemia, Hypocalcemia, Hypomagnesemia 
 Female Gender 
 Hepatic Impairment/Renal Impairment 
(https://crediblemeds.org/) 
 
 
 
 
CLINICALLY SIGNIFICANT INTERACTIONS 
Drug Ciprofloxacin Levofloxacin Moxifloxacin 
Antacids 
(Al/Mg) 
Cmax dec 30-94% 
 
Cmax dec 37-65% 
AUC dec 22-44% 
 
Cmax dec 40% 
AUC dec 23-60% 
 
Sucralfate AUC dec 96% 
 
No significant 
interaction if levo 
given 2 hrs before 
or after sucralfate 
 
Recommended 
that use be 
avoided 
AUC dec 6.56 to 
2.62 
 
 
Iron AUC dec 60% Cmax dec 45% 
AUC dec 19% 
 
 
Cmax dec 59% 
AUC dec 39% 
 
Calcium Dec bioavailability 
by 30% 
Dec bioavailability 
18%,  
No Interaction 
HOW ARE THESE DRUG INTERACTIONS HANDLED? 
Reference Ciprofloxacin Levofloxacin Moxifloxacin 
Package Insert Take at least 2 hrs before or 
6 hrs after 
magnesium/aluminum 
antacids, sucralfate, videx, 
or other products containing 
calcium, iron or zinc 
 
Should not be taken with 
dairy products (like milk or 
yogurt or calcium-fortified 
juices) 
 
May be taken with a meal 
that contains these products. 
Take at least 2 hrs 
before or 2 hours 
after antacids 
(Mg/Al), 
multivitamins 
containing iron or 
zinc, sucralfate, DDI 
(Videx) 
 
Calcium less 
Take at least 4 hrs 
before or 8 hrs after 
antacids  (Mg/Al), 
multivitamins 
containing iron or 
zinc,  sucralfate, 
DDI (Videx) 
 
Does not interact 
with calcium.  No 
interaction with 1 
cup of yogurt 
 
 Patients were administered levofloxacin within 2 hours of  
divalent/trivalent cations 77 % of the time. 
 
 
Comparison of percentages of doses 
that were taken with interacting drugs 
Risk of Resistance 
Adjusted OR (95% CI) 
P value 
100% vs <100% 1.43 (1.04 – 1.96) 0.03 
≥75% vs <75% 1.33 (0.98 – 1.82) 0.06 
≥50% vs <50% 1.52 (1.13 – 2.06) 0.006 
≥25% vs <25% 1.31 (0.97 – 1.77) 0.07 
100% vs 0% 1.36 (1.00 – 1.86) 0.05 
Infect Control Hosp Epidemiol 2008;29:975-977 
Strep Staph Enterococcus E. Coli 
Klebsiella 
Proteus 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
Azithromycin + + - 
 
- + - + - 
Clarithromycin + + - 
 
- + - + - 
Erythromycin + + - - ± - + - 
Clev Clin J Med 2013;80(9):539 
If azithromycin is prescribed: 
• Correct electrolyte abnormalities 
• Avoid polypharmacy with multiple QTc-prolonging medications. 
Strep Staph Enterococcus E. Coli 
Klebsiella 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
Doxycycline + MSSA 
MRSA 
+ 
 
+ + - + - 
Minocycline + MSSA 
MRSA 
 
+ 
 
+ + - + - 
Doxycycline Minocycline Tetracycline 
Oral Dose 100mg 100mg 500mg 
Bioavailability 95% 95-100% 77-88% 
Half-life (hrs) 18-25 16 8.5 
% eliminated 
urine 
35-60% 5-12% 30% 
Creatinine 
Clearance 
Doxycycline Urine 
Concentrations (% of 
dose) 
Group 1 
99 – 131 ml/min 
33.5 ug/ml ± 16.9  (32%) 
Group 2 
19 - 83 ml/min 
20.7 ± 11.9 ug/ml (18%) 
Group 3 
< 10 ml/min 
1.3 ± 0.3 ug/ml   (1.8%) 
Heaney D Clin Pharmacol Ther 1978, Campistron G Drug Research 1986;36(2), Alestig K Scand J Infect Dis 1973;5:193-198. 
Breakpoint = 4 ug/ml  
System Adverse Reactions 
GI GI distress – Less with doxycycline 
Esophagitis/Esophageal ulceration 
 
Is there a difference with products?  Hyclate vs Monohydrate 
CNS  Minocycline: 
 CNS – vertigo, light-headedness, loss of balance, 
dizziness, and tinnitus –on 2nd to 3rd day of therapy 
 Autoimmune disorders: lupus, hepatitis, serum sickness, 
vasculitis, pneumonitis 
Skin Bluish gray nail, skin, and sclera pigment 
 Package Insert Dosing Recommendations 
 
 
 
 Pharmacodynamics (in-vitro) 
 2-4 times MIC =    Time Dependent  
 8-16 times MIC = Concentration Dependent 
 
 With half-life = 22 hours, steady state would be reached in 4-5 days 
 Interesting recommendation for serious infections 
 200mg IV/PO q 12h x 3 days, 100mg IV/PO q 12h 
Cunha Clin Microbiol Infection 2000; 6(5): 270-273. Cunha Clin Infect Dis 2003;37:870,  Doxycycline Hyclate Package Insert 6/25/14  
Drug Doxycycline Minocycline Tetracycline 
Antacids 
(Al/Mg) 
Take Doxy 1-2 hrs before 
or 6 hrs after antacids 
 
Take minocycline 1-2 
hrs before or 6 hrs 
after antacids 
 
Take TCN 1-2 hrs 
before or 6 hrs after 
antacids 
Decrease absorption 
by 90% 
Calcium Not affected by milk 
products 
Not affected by milk 
products 
Decrease absorption 
by 50-80%, milk 
products 
Iron Give 3 hrs before or 2 
hours after doxy dose 
 
Decrease concentrations 
by 80-90% 
Give 3 hours before 
or 2 hours after 
minocycline dose. 
Give 3 hrs before or 2 
hours after TCN dose 
 
Decrease 
concentrations by 40-
50% 
Doxycycline and Minocycline are affected less by divalent and trivalent cations than 
tetracycline 
Strep Staph Enterococcus E. Coli 
Klebisella 
Proteus 
H.influenzae 
M.catarrhalis 
Pseudomonas Atypical Anaerobe 
Clindamycin + MRSA 
MSSA 
- 
 
- - - - + 
Important Facts: 
• High risk of Clostridium difficile 
• Gastrointestinal side effects, especially when oral doses are > 450mg po 4 times 
daily 
 
Bergman et al. BMC Geriatrics 2011;11:69 
 Antibiotic prophylaxis represents 20-30% of all antibiotic prescription in LTCF. 
 UTI prophylaxis - 51.4%  
 
 Limited data on efficacy in nursing home population 
 Cochrane review in nonpregnant women antibiotic vs placebo: 
 Microbiologic recurrence during prophylaxis RR 0.21 (0.13 – 0.34) 
 Antibiotic side effects RR 1.78 (1.06 – 3.00) 
 Microbiologic recurrence after prophylaxis RR 0.82 (0.44 – 1.53) 
 
 Antibiotic prophylaxis should be discouraged! 
 
Latour K Pharmacoepidemiology Drug Safety 2012;21:937-944, Albert X The Cochrane database of systemic reviews 2004; CD001209 
 Antiseptic: Prophylactic/suppressive treatment 
 Methenamine    Formaldehyde 
 Urine must be acidic pH < 6 
 Use with Vitamin C (1-4g up to 12g), prunes, or plums 
 Dose 
 Hippurate: 1g po twice daily 
 Mandelate: 1g po 4 times daily 
 Contraindicated: renal (clearance < 50 ml/min),hepatic disease.  Severe 
dehydration, hyperphosphatemia, with sulfonamides – precipitates in urine 
 Do not use in patients with catheters 
 ADRs: nausea, vomiting, dyspepsia, diarrhea, rash 
 2011: formaldehyde declared carcinogenic: limit duration. 
Patient Population Outcome Relative 
Risk 
95% CI 
Pts without renal tract 
abnormalities 
Symptomatic UTI: 0.24 
 
0.07-0.89 
Bacteriuria: 0.56 0.37-0.83 
Short term treatment 
1 week or less 
Symptomatic UTI 0.14 0.05 – 0.38 
Pts with renal tract 
abnormalities 
Symptomatic UTI: 1.54 0.38-6.20 
Bacteriuria: 1.29 0.54 – 3.07 
Cochrane Review of 13 studies with Methenamine hippurate 
Lee BS Cochrane Database Syst Rev. 2012 Oct 17;10:CD003265. 
lavery@sjfc.edu 
